Leinco Technologies

Anti-Human HLA-DQ (MHC Class II) - Purified in vivo GOLD™ Functional Grade

Product Code:
 
LEI-H262
Product Group:
 
Primary Antibodies
Host Type:
 
Mouse
Antibody Isotype:
 
IgG2a
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
1a3
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Flow Cytometry
  • Immunoprecipitation (IP)
  • In Vivo Assay
  • Western Blot (WB)
Shipping:
 
2-8°C
Storage:
 
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-H262-1.0mg1.0 mg£175.00
Quantity:
LEI-H262-5.0mg5.0 mg£380.00
Quantity:
LEI-H262-25mg25 mg£1,014.00
Quantity:
LEI-H262-50mg50 mg£1,556.00
Quantity:
LEI-H262-100mg100 mg£2,159.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Antigen Distribution:
HLA-DQ is expressed on antigen-presenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
in vivo GOLD™, Purified in vivo Functional Grade
Format:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
Unknown
Long Description:
HLA-DQ antibody, clone 1a3, recognizes the major histocompatibility complex (MHC) class II molecule Human Leukocyte Antigen - DQ isotype (HLA-DQ). MHC class II is constitutively expressed on human professional antigen-presenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation2. HLA-DQ consists of two transmembrane proteins, a 35 kDa α (heavy) chain and 29 kDa β (light) chain3 encoded by the HLA-DQA1 and HLA-DQB1 genes, respectively, located in the HLA complex of chromosome 6. The N-terminal α1 and β1 domains form the antigen-binding groove, which binds 13-25 aa peptides derived from exogenous antigens4. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling5. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation6 and can transduce signals into T cells, enhancing T cell proliferation and activity7. Specific alleles of HLA-DQ are associated with autoimmune diseases, including celiac disease8 and type 1 diabetes9, and graft-versus-host disease10.
NCBI Gene:
3177
Purity:
?95% monomer by analytical SEC, >95% by SDS Page
Target:
HLA-DQ

References

1. Shookster L, et al. (1987) Hum Immunol. 20(1):59-70 2. Holling TM, Schooten E, van Den Elsen PJ. (2004) Hum Immunol. 65(4):282-90 3. Mitaksov V, Fremont DH. (2006) J Biol Chem. 281(15):10618-25 4. Wieczorek M, et al. (2017) Front Immunol. 8:292 5. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921 6. Barnaba V, et al (1994) Eur J Immunol. 24(1):71-5 7. Di Rosa F, et al. (1993) Hum Immunol. 38(4):251-60 8. Casta?o L, et al. (2004) J Pediatr Gastroenterol Nutr. 39:80?84 9. Cucca F, et al. (1993) Hum Immunol. 37:85 ?94 10. Petersdorf EW, (1996) Proc Natl Acad Sci USA. 93(26):15358-63